



ALKLINIC+

EVOLVING ALK + NSCLC OUTCOMES

SAVE THE DATE

01/08/2026

16:30 - 18:45



We would like to invite you to the main session of the ALKlinic webinar—which we consider highly relevant to your clinical practice—taking place from 16:30 to 18:45. During this session, key topics regarding the comprehensive management of ALK+ patients will be addressed, including:

16:30 - 16:50	ALK+ NSCLC in 2026: CROWN – Where do we go from here?	Prof. Tony Mok
16:50–17:10	Consensus Voting & Panel Discussion	Professors: Jessica Lin, Solange Peters, Ross Soo and Tony Mok
17:10–17:30	Practical Management of ALK+ NSCLC Resistance	Prof. Jessica Lin
17:30–17:50	Consensus Voting & Panel Discussion	Professors: Jessica Lin, Solange Peters, Ross Soo and Tony Mok
17:50–18:40	Case-based Discussions	Dr. Fedor Moiseenko Panel Discussion Professors: Jessica Lin, Solange Peters, Ross Soo and Tony Mok
18:40–18:45	Summary & Closing	Prof. Tony Mok and Prof. James Yang

ALK+ = Anaplastic Lymphoma Kinase-positive; NSCLC = Non-Small Cell Lung Cancer

[REGISTER HERE](#)



Pfizer (Malaysia) Sdn Bhd 197801003134 (40131-T)
Level 10 & 11, Wisma Averis, Tower 2, Avenue 5, Bangsar South,
No. 8 Jalan Kerinchi, 59200 Kuala Lumpur, Malaysia
Tel: 603.22816000 Fax: 603.22816388 www.pfizer.com.my

For Healthcare Professionals only
PP-LOR-MYS-03286-26JUN2026